The Shanghai Institute of Infectious Disease and Biosecurity announced on April 18, 2026, that its SII-007 influenza antibody has achieved industrial application after successful patent transfer and funding integration.
The antibody neutralizes multiple flu strains and works immediately after administration
SII-007 broadly neutralizes the influenza virus and provides immediate protection as a passive immunotherapy, taking effect right after aerosol inhalation without a two-week induction period.
It addresses challenges from frequent virus mutations by overcoming the broad-spectrum limitations of traditional antibodies through AI-integrated synthetic immunology research.
Development cost totaled 21 million yuan with Fosun Pharma partnership advancing industrialization
The project was developed by a team led by Ying Tianlei, a part-time SIIDB principal investigator, at a cost of 21 million yuan ($3.1 million), including transfer fees and post-sales revenue sharing.
By the end of 2025, SIIDB had transferred technology valued at over 44.5 million yuan, and the SII-007 antibody was connected to a Fosun Pharma fund within one month of patent completion to advance industrial use.
Regulatory approval expected by year-end to enter clinical trials
Ying Tianlei stated the technology completed patent transfer in February 2026 and is expected to receive regulatory approval from China’s drug administration by the end of the year to enter the clinical trial phase.
What is SII-007 and how does it differ from traditional flu antibodies?
SII-007 is a broadly neutralizing influenza antibody developed using AI and synthetic immunology to overcome the narrow activity of traditional antibodies, effective against multiple epidemic strains.
How is the antibody administered and what are its practical advantages?
It is delivered via aerosol inhalation, requires low doses, takes effect immediately after administration, and offers high stability to prevent severe influenza.
